Aktuellt
SENASTE
Redeye maintains BioArctic's valuation at SEK 250 per share after the report today. The available clinical data and regulatory expectations support a higher than average (for this sector) likelihood of approval for lecanemab. The heat is on for BioArctic this quarter (Q2) and next. Beoynd this, we expect further efforts by BioArctic to bring more candidates into pre-clinical and clinical development.
LÄS MER
